Back to top
more

Revvity, Inc. (RVTY)

(Delayed Data from NYSE)

$88.23 USD

88.23
1,601,109

+0.33 (0.38%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $88.23 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View

by Zacks Equity Research

Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.

Zacks Equity Research

Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Revvity (RVTY) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and +1.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Revvity (RVTY) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?

by Zacks Equity Research

RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.

Zacks Equity Research

Wall Street's Insights Into Key Metrics Ahead of Revvity (RVTY) Q2 Earnings

by Zacks Equity Research

Beyond analysts' top-and-bottom-line estimates for Revvity (RVTY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

Zacks Equity Research

GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

GENEDX HOLDINGS (WGS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Revvity (RVTY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Pediatrix Medical Group (MD) Down 3.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

RVTY Stock Falls Despite the Latest Launch of Automated Instrument

by Zacks Equity Research

Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.

Zacks Equity Research

Company News for Apr 29, 2025

by Zacks Equity Research

Companies In The News Are: DPZ, RVTY, OPRA, INMD.

Zacks Equity Research

RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up

by Zacks Equity Research

Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.

Zacks Equity Research

Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Revvity (RVTY) delivered earnings and revenue surprises of 5.21% and 0.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Revvity (RVTY) Could Beat Earnings Estimates Again

by Zacks Equity Research

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?

by Zacks Equity Research

RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.

Zacks Equity Research

Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline

by Zacks Equity Research

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

by Zacks Equity Research

RVTY's strong product portfolio raises optimism about the stock.

Zacks Equity Research

Revvity Stock Tumbles Despite Expanding Genomics England Alliance

by Zacks Equity Research

RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.

Zacks Equity Research

Do Options Traders Know Something About Revvity (RVTY) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Revvity (RVTY) stock based on the movements in the options market lately.

Zacks Equity Research

RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust

by Zacks Equity Research

Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.

Zacks Equity Research

Revvity (RVTY) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Revvity (RVTY) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Revvity (RVTY) delivered earnings and revenue surprises of 4.41% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.